APA (7th ed.) Citation

A, D., S, P., S, S., D, C., & K, G. (2024). An Open-Label, Investigator-Initiated, Single-Centre Pilot Study to Determine the Safety and Efficacy of Tofacitinib in Resistant Chronic Spontaneous Urticaria. Indian journal of dermatology, 69(4), 312. https://doi.org/10.4103/ijd.ijd_1085_23

Chicago Style (17th ed.) Citation

A, De, Pal S, Singh S, Chakroborty D, and Godse K. "An Open-Label, Investigator-Initiated, Single-Centre Pilot Study to Determine the Safety and Efficacy of Tofacitinib in Resistant Chronic Spontaneous Urticaria." Indian Journal of Dermatology 69, no. 4 (2024): 312. https://doi.org/10.4103/ijd.ijd_1085_23.

MLA (9th ed.) Citation

A, De, et al. "An Open-Label, Investigator-Initiated, Single-Centre Pilot Study to Determine the Safety and Efficacy of Tofacitinib in Resistant Chronic Spontaneous Urticaria." Indian Journal of Dermatology, vol. 69, no. 4, 2024, p. 312, https://doi.org/10.4103/ijd.ijd_1085_23.